IL282923B2 - Methods and preparations for diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers - Google Patents

Methods and preparations for diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers

Info

Publication number
IL282923B2
IL282923B2 IL282923A IL28292321A IL282923B2 IL 282923 B2 IL282923 B2 IL 282923B2 IL 282923 A IL282923 A IL 282923A IL 28292321 A IL28292321 A IL 28292321A IL 282923 B2 IL282923 B2 IL 282923B2
Authority
IL
Israel
Prior art keywords
ifny
patients
seq
hlh
mas
Prior art date
Application number
IL282923A
Other languages
English (en)
Hebrew (he)
Other versions
IL282923B1 (en
IL282923A (en
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of IL282923A publication Critical patent/IL282923A/en
Publication of IL282923B1 publication Critical patent/IL282923B1/en
Publication of IL282923B2 publication Critical patent/IL282923B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
IL282923A 2015-05-07 2016-05-09 Methods and preparations for diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers IL282923B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562158153P 2015-05-07 2015-05-07
US201562221393P 2015-09-21 2015-09-21
US201562246949P 2015-10-27 2015-10-27
PCT/EP2016/060360 WO2016177913A1 (en) 2015-05-07 2016-05-09 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Publications (3)

Publication Number Publication Date
IL282923A IL282923A (en) 2021-06-30
IL282923B1 IL282923B1 (en) 2023-06-01
IL282923B2 true IL282923B2 (en) 2023-10-01

Family

ID=56008603

Family Applications (3)

Application Number Title Priority Date Filing Date
IL282923A IL282923B2 (en) 2015-05-07 2016-05-09 Methods and preparations for diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers
IL302519A IL302519A (en) 2015-05-07 2016-05-09 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
IL255440A IL255440B (en) 2015-05-07 2017-11-05 Methods and preparations for the diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL302519A IL302519A (en) 2015-05-07 2016-05-09 Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
IL255440A IL255440B (en) 2015-05-07 2017-11-05 Methods and preparations for the diagnosis and treatment of disorders in patients with high levels of chemokine C.-X.-C. Ligand 9 and other biomarkers

Country Status (13)

Country Link
US (2) US11034760B2 (enExample)
EP (1) EP3292147A1 (enExample)
JP (4) JP2018515493A (enExample)
KR (1) KR20180004254A (enExample)
CN (1) CN107849127A (enExample)
AU (1) AU2016257023B2 (enExample)
BR (1) BR112017023867A2 (enExample)
CA (1) CA2985001A1 (enExample)
EA (1) EA037532B1 (enExample)
IL (3) IL282923B2 (enExample)
MX (3) MX2017014294A (enExample)
SG (1) SG10202108996PA (enExample)
WO (1) WO2016177913A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292147A1 (en) 2015-05-07 2018-03-14 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
MX2019004766A (es) * 2016-10-24 2019-09-27 Novimmune Sa Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma.
CN109164266B (zh) * 2017-11-27 2021-09-24 首都医科大学附属北京友谊医院 细胞因子在区分淋巴瘤相关噬血细胞综合征和淋巴瘤中的应用
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
WO2019173676A1 (en) * 2018-03-09 2019-09-12 Children's Hospital Medical Center Compositions and methods for the treatment of macrophage activation syndrome
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment
JP7396213B2 (ja) * 2020-06-22 2023-12-12 Tdk株式会社 データ解析システム、データ解析方法及びデータ解析プログラム
CN115812671B (zh) * 2022-11-17 2024-07-19 青岛大学 帕金森病动物模型的建立方法及其应用
WO2024254401A1 (en) 2023-06-09 2024-12-12 Children's Hospital Medical Center Treatment of stem cell graft failure
CN118266439A (zh) * 2024-04-26 2024-07-02 倍科为(天津)生物技术有限公司 一种斑马鱼继发性噬血细胞综合征模型的构建方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109191A2 (en) * 2005-01-27 2006-10-19 Novimmune S.A. Human anti-interferon gamma antibodies and methods of use thereof
WO2013078378A1 (en) * 2011-11-23 2013-05-30 Amgen Inc. Methods of treatment using an antibody against interferon gamma

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4599306A (en) 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69322289T2 (de) 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US20030059428A1 (en) 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
US6534059B2 (en) 2001-06-05 2003-03-18 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US6861056B2 (en) 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
JP2005529152A (ja) 2002-05-17 2005-09-29 プロテイン デザイン ラブス インコーポレイティド 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
US20040052791A1 (en) 2002-05-22 2004-03-18 Rolf Ehrhardt Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
AU2003285874A1 (en) 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
GB0314461D0 (en) 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7504106B2 (en) 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
GB0607943D0 (en) 2006-04-21 2006-05-31 Novartis Ag Biomarkers for chronic transplant dysfunction
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
PL2234600T3 (pl) 2007-12-21 2015-02-27 Hoffmann La Roche Preparat przeciwciała
US20110256149A1 (en) 2008-10-09 2011-10-20 Medimmune, Llc Antibody formulation
CN102413839A (zh) 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
PT2691112T (pt) * 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
US20170189528A1 (en) 2014-06-10 2017-07-06 Meiji Seika Pharma Co., Ltd. Stable aqueous adalimumab formulation
EP3237000A1 (en) * 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
EP3292147A1 (en) 2015-05-07 2018-03-14 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
MX2019004766A (es) 2016-10-24 2019-09-27 Novimmune Sa Metodos, composiciones y regimenes de dosificacion para tratar o prevenir indicaciones relacionadas con interferon-gamma.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109191A2 (en) * 2005-01-27 2006-10-19 Novimmune S.A. Human anti-interferon gamma antibodies and methods of use thereof
WO2013078378A1 (en) * 2011-11-23 2013-05-30 Amgen Inc. Methods of treatment using an antibody against interferon gamma

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, NCT01818492 ON 2015_03_08: CLINICALTRIALS.GOV ARCHIVE, 8 March 2015 (2015-03-08) *
ANONYMOUS,, NOVIMMUNE -- NEWS: EUROPEAN COMMISSION AWARDS EUR 6 MILLION FP7 GRANT TO SUPPORT CLINICAL DEVELOPMENT OF NI-0501 TO 'FIGHT HLH, 15 October 2012 (2012-10-15) *
ANONYMOUS,, NOVIMMUNE -- NEWS: NEW DRUG BEGINS TESTING AS FIRST-LINE TREATMENT FOR FATAL CHILDHOOD DISEASE., 16 March 2015 (2015-03-16) *
ANONYMOUS,, PUBLIC SUMMARY OF OPINION ON ORPHAN DESIGNATION RECOMBINANT HUMAN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY FOR THE TREATMENT OF HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, 10 June 2016 (2016-06-10) *
BRACAGLIA, C., ET AL., ANTI INTERFERON-GAMMA (IFN[GAMMA]) MONOCLONAL ANTIBODY TREATMENT IN A PATIENT CARRYING AN NLRC4 MUTATION AND SEVERE HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS., 28 September 2015 (2015-09-28) *
BRADY MILLER ET AL,, HEMOPHAGOCYTOSIS IN ADULTS (HEMOPHAGOCYTIC SYNDROME), 2 November 2009 (2009-11-02) *
DE MIN, CRISTINA, ET AL., INNOVATIVE APPROACH FOR THE IDENTIFICATION OF AN APPROPRIATE DOSE REGIMEN OF A TARGETED TREATMENT, NI-0501, AN ANTI-INTERFERON GAMMA (IFNG) ANTIBODY, IN PATIENTS WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH): ABSTRACT NUMBER: 3097., 29 September 2015 (2015-09-29) *
DUARTE, G. V., ET AL., OSTEOPONTIN, CCL5 AND CXCL9 ARE INDEPENDENTLY ASSOCIATED WITH PSORIASIS, REGARDLESS OF THE PRESENCE OF OBESITY., 1 August 2015 (2015-08-01) *
GOSWAMI, SUMIT, ET AL., DEVELOPMENTS AND CHALLENGES FOR MAB-BASED THERAPEUTICS., 16 August 2013 (2013-08-16) *
HARDEN, JAMIE L., ET AL., HUMANIZED ANTI–IFN-G (HUZAF) IN THE TREATMENT OF PSORIASIS., 1 February 2015 (2015-02-01) *
JORDAN, MICHAEL B., ET AL., AN ANIMAL MODEL OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH): CD8+ T CELLS AND INTERFERON GAMMA ARE ESSENTIAL FOR THE DISORDER., 8 April 2004 (2004-04-08) *
JORDAN, MICHAEL B., ET AL., HOW I TREAT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS., 13 October 2011 (2011-10-13) *
SCHMID, JANA PACHLOPNIK, ET AL., NEUTRALIZATION OF IFN[GAMMA] DEFEATS HAEMOPHAGOCYTOSIS IN LCMV-INFECTED PERFORIN- AND RAB27A-DEFICIENT MICE., 4 May 2009 (2009-05-04) *

Also Published As

Publication number Publication date
CA2985001A1 (en) 2016-11-10
EA037532B1 (ru) 2021-04-08
IL255440A0 (en) 2017-12-31
MX2022001008A (es) 2022-02-22
IL282923B1 (en) 2023-06-01
US20210101972A1 (en) 2021-04-08
AU2016257023A1 (en) 2017-11-30
IL255440B (en) 2021-08-31
MX2024001909A (es) 2024-02-28
MX2017014294A (es) 2018-08-09
IL282923A (en) 2021-06-30
JP2018515493A (ja) 2018-06-14
AU2016257023B2 (en) 2022-06-30
JP7685008B2 (ja) 2025-05-28
US11034760B2 (en) 2021-06-15
EP3292147A1 (en) 2018-03-14
US12275785B2 (en) 2025-04-15
JP2025118898A (ja) 2025-08-13
SG10202108996PA (en) 2021-09-29
US20160326244A1 (en) 2016-11-10
KR20180004254A (ko) 2018-01-10
JP2023090964A (ja) 2023-06-29
JP2021100943A (ja) 2021-07-08
EA201792447A1 (ru) 2018-05-31
BR112017023867A2 (pt) 2018-07-24
CN107849127A (zh) 2018-03-27
WO2016177913A1 (en) 2016-11-10
IL302519A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
US12275785B2 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
US12195530B2 (en) Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
JP7562074B2 (ja) インターフェロンガンマ関連の適応症を処置または予防するための方法、組成物および投薬レジメン
Prasad et al. Rheumatoid arthritis: advances in treatment strategies
AU2019377515A1 (en) Treatment for giant cell arteritis
Majchrzak et al. Biologic therapy in Crohn’s disease–what we have learnt so far
EA042261B1 (ru) Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний
EA049189B1 (ru) Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
Byng-Maddick Differential effects of anti-TNF therapies for inflammatory arthritides on immune responses to Mycobacterium tuberculosis